|
|
Article: NeoPharm's Cintredekin Besudotox Continues to Show Evidence of Prolonged Overall Survival in Patients with Recurrent Glioblastoma Multiforme.
- Article from:
- Business Wire
- Article date:
- April 24, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN FRANCISCO -- NeoPharm, Inc. (Nasdaq: NEOL):
--Median Survival Of More Than One Year Observed
--Catheter Placement Key Predictor of Prolonged Survival
NeoPharm, Inc. (Nasdaq:NEOL) today announced that cintredekin besudotox (IL13-PE38QQR) continues to show evidence of prolonged overall survival in patients with recurrent glioblastoma multiforme (GBM). Updated data for GBM patients treated in Phase I/II studies and results from a Phase I/II subset analysis is being presented at the 74th Annual Meeting of the American Association of Neurological Surgeons (AANS) held in San Francisco on Monday, April 24, 2006.
Sandeep Kunwar, MD, ...